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Edited by Gianni CesareniAbstract Tumor necrosis factor receptor associated factor 6
(TRAF6) is an important signaling molecule involved in a diverse
array of physiological processes. It has been proposed that
TRAF6, a RING ﬁnger-containing protein, acts as a ubiquitin
ligase (E3) and a target for Lys-63 linked polyubiquitination
mediated by Ubc13–Uev, a ubiquitin conjugating (E2) complex.
However, the physical interaction between TRAF6 and this E2
complex has not been reported. We used the yeast two-hybrid
assay to demonstrate that TRAF6 indeed interacts with the E2
complex through its direct binding to Ubc13. Either a single
Cys-to-Ser substitution within the TRAF6 RING ﬁnger domain
or an amino acid substitution on the Ubc13 surface, that is
predicted to interact with RING ﬁnger proteins, is able to abolish
the interaction. In addition, we found that TRAF6 can interact
with itself and this self-interaction domain is mapped to the N-
terminus containing the RING ﬁnger motif. Based on this study
and our previous Ubc13–Uev structural analysis, the interface of
Ubc13-TRAF6 RING ﬁnger can be predicted.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Tumor necrosis factor receptor associated factor 6 (TRAF6)
plays a crucial role in various cellular processes including
adaptive and innate immunity, inﬂammation, bone metabo-
lism as well as the development of several tissues including
lymph nodes, mammary glands, skin and the central nervous
system (for a recent review, see [1]). Transgenic mice defective
in TRAF6 exhibit exencephaly and deregulated apoptosis
within the developing central nervous system as well as severe
osteopetrosis and have impaired osteoclast function [2,3]. It
was recently found [4] that TRAF6 is a signal transducer in the
NF-jB pathway and activates IjB kinase (IKK). This kinase is
able to phosphorylate IjB and cause its rapid degradation by
the ubiquitin (Ub)-proteasome pathway. TRAF6 is also re-* Corresponding author. Fax: +1-306-966-4311.
E-mail address: wei.xiao@usask.ca (W. Xiao).
Abbreviations: b-gal, b-galactosidase; IKK, IjB kinase; TRAF, tumor
necrosis factor receptor associated factor; hTRAF6, human TRAF6;
mTRAF6, mouse TRAF6; Ub, ubiquitin; Ubc or E2, ubiquitin
conjugating enzyme; Ubl or E3, ubiquitin ligase; Uev, Ubc variant; 3-
AT, 1,2,4-amino triazole
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JNK-p38 kinase pathway [5]. The above two TRAF6 activities
require a heterodimeric Ub-conjugating enzyme (Ubc or E2)
composed of Ubc13 and a Ubc variant (Uev), Uev1A or
Mms2. This Ubc13–Uev complex is known to catalyze the
synthesis of unique poly-Ub chains linked through Lys-63 [6],
an activity that is required for both IKK and MKK6 phos-
phorylation by the TAK1 kinase complex [4,5]. TRAF6 con-
tains ﬁve zinc ﬁnger repeats and a RING ﬁnger motif [7],
suggesting that it may act as a Ub ligase (Ubl or E3). Inter-
estingly, TRAF6 is also the target of Ubc13–Uev mediated
Lys-63 ubiquitination [5]. If TRAF6 indeed functions as an E3,
one would expect direct physical interaction between TRAF6
and its cognate E2. Despite repeated attempts, however, evi-
dence for the physical interaction between TRAF6 and
Ubc13–Uev has not been obtained through in vitro studies (J.
Chen, personal communication and our own observations). To
address whether TRAF6 interacts with Ubc13–Uev through a
direct interaction with either Ubc13 or Uev, we performed the
yeast two-hybrid assay and demonstrated a direct interaction
between TRAF6 and Ubc13. Furthermore, deletion and site-
directed mutagenesis mapped the self- and Ubc13-interaction
region of TRAF6 to its N-terminus, which contains the RING
ﬁnger motif.2. Materials and methods
2.1. Yeast strains and cell culture
Saccharomyces cerevisiae haploid strains used in this study include
Y190 (MATa gal4 gal80 his3 trp1 ade2-101 ura3 leu2 URA3::PGAL1-
lacZ LYS2::PGAL1-HIS3, a gift from Dr. D. Gietz, University of
Manitoba, Winnipeg, Canada) and PJ69-4a (MATa trp1-901 leu2-3,
112 ura3-52 his3-200 gal4D gal80D PGAL2-ADE2 LYS2::PGAL1-HIS3
met2::PGAL7-lacZ, a gift from Dr. P. James, University of Wisconsin at
Madison, USA). Yeast cells were cultured at 30 C either in a complete
YPD medium or in a synthetic dextrose (SD) medium supplemented
with necessary nutrients as recommended [8]. To make plates, 2% agar
was added to either YPD or SD medium prior to autoclaving.
Yeast cells were transformed using a dimethyl sulfoxide enhanced
LiAc method as described [9].
2.2. Plasmids
The full-length mouse TRAF6 (mTRAF6) cDNA was obtained from
Dr. J. Chen (University of Texas Southwestern Medical Center,
Dallas, USA) and the full-length human TRAF6 (hTRAF6) cDNA
was obtained from Dr. V.M. Dixit (Genentech, Inc., San Francisco,
USA). Both TRAF6 genes were cloned as EcoRI–SalI fragments into
pGBT9 and pGAD424 [10] to form pGBT-mTRAF6, pGAD-
mTRAF6, pGBT-hTRAF6 and pGAD-hTRAF6. To determine do-
main(s) required for TRAF6 self-interaction and the interaction withation of European Biochemical Societies.
Fig. 1. Interaction of mTRAF6 with Ubc13 in yeast two-hybrid assays.
A: mTRAF6-Ubc13 interaction is independent of their fusion partners.
Y190 cells, co-transformed with Gal4AD and Gal4BD constructs, were
tested by a ﬁlter assay (two independent colonies for each transfor-
mation) and a quantitative b-gal assay as expressed in MU. B:
mTRAF6 interacts with Ubc13 but not with Uev1A or hMms2. PJ69-
4a cells, co-transformed with Gal4AD and Gal4BD constructs, were
replicated on SD-Trp-Leu-Ade and SD-Trp-Leu-His+5 mM 3-AT
plates and the plates were incubated for three days at 30 C.
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follows. Plasmid pGAD-mTRAF6N containing coding sequences for
the N-terminal 279 amino acids of mTRAF6 was made by HpaI and
BglII digestion of pGAD-mTRAF6. The BglII cohesive end was ﬁlled
using the Klenow fragment of Escherichia coli DNA polymerase I and
the resulting DNA was self-ligated. To create pGBT-mTRAF6C
containing coding sequences for amino acids 293–530 of mTRAF6,
pGBT-mTRAF6 was digested with EcoRI and SmaI. The EcoRI co-
hesive end was ﬁlled using Klenow and the resulting DNA was self-
ligated in the presence of an 8-bp BglII linker to restore the reading
frame of the fusion gene.
The human UBC13 open reading frame was PCR ampliﬁed as an
EcoRI–SalI fragment and cloned into pGBT9 and pGAD424 to form
pGBT-hUBC13 and pGAD-hUBC13, respectively. hMMS2 and
UEV1A cDNAs were isolated as previously reported [11]. Their open
reading frames were PCR ampliﬁed as BamHI fragments and cloned
into pGAD424 in a correct orientation to form pGAD-hMMS2 and
pGAD-UEV1A, respectively. The coding regions of hMMS2 and
UEV1A without stop codons were PCR ampliﬁed as BamHI–SalI
fragments and cloned into pG4BD-1 (received from Dr. R.B. Brazas,
University of California, San Francisco, USA) to form phMMS2-
G4BD and pUEV1A-G4BD, respectively, as C-terminal fusions to
Gal4BD.
Yeast two-hybrid plasmids containing a site-speciﬁc mutation within
mTRAF6 that results in the C70S substitution and within hUBC13 that
results in the M64A substitution were constructed by a mega-primer
approach [12].
2.3. Yeast two-hybrid analyses
The yeast two-hybrid strain Y190 was co-transformed with diﬀerent
combinations of pGBT and pGAD-based plasmids. The co-trans-
formed colonies were initially selected on SD-Trp-Leu. For each
transformation, at least ﬁve independent colonies were replica plated
onto SD-Trp-Leu plates to assess b-galactosidase (b-gal) activity by a
ﬁlter assay as previously described [13] and onto SD-Trp-Leu-His with
various concentrations of 1,2,4-amino triazole (3-AT) to test the ac-
tivation of the PGAL1-HIS3 gene.
The yeast two-hybrid strain PJ69-4a [14] was co-transformed with
diﬀerent combinations of Gal4BD and Gal4AD constructs. The co-
transformed colonies were initially selected on SD-Trp-Leu. For each
transformation, at least ﬁve independent colonies were replica plated
onto SD-Trp-Leu-His+3-AT to test the activation of the PGAL1-HIS3
gene and onto SD-Leu-Trp-Ade plates to test the activation of PGAL2-
ADE2.
2.4. Quantitative b-gal assay
The b-gal assay was performed as previously described [15] to
quantitatively measure the strength of yeast two-hybrid interactions.
Brieﬂy, 0.5 ml of overnight culture of Y190 double transformants was
used to inoculate 2.5 ml of fresh selective medium. When the cell
density reached an OD600 nm of approximately 0.7–1.0, 1 ml of culture
was used to determine absorbance (cell density) at OD600 nm. Cells
from the other 2 ml of culture were collected by centrifugation and
used for the b-gal assay. b-Gal activity was standardized by sub-
tracting the b-gal activity found in the co-transformants containing
vectors pGAD424 and pGBT9. b-Gal activity is expressed in Miller
Units (MU) [16]. Results shown are the average of at least three in-
dependent experiments.
2.5. Western-blot analysis
Y190 cells transformed with two-hybrid constructs were grown in
10 ml SD-Trp or SD-Leu liquid media at 30 C overnight, subcultured
in the corresponding fresh medium and allowed to grow at 30 C until
a cell density of OD600 nm of 0.8 was reached. Yeast cells were har-
vested by centrifugation at 3000 g for 10 min at 4 C. Yeast crude cell
extracts were made with the YeastBuster protein extraction reagent
(Novagen, Darmstadt, Germany) following the manufacturer’s in-
structions. The yeast cell extract was run on a 10% SDS–PAGE gel and
then transferred to a PVDF membrane (polyvinylidene diﬂuoride, Bio-
Rad Laboratories, Hercules, CA, USA). Membranes were incubated in
a blocking solution (PBS, 3% non-fat milk) at room temperature for
1 h. Anti-Gal4BD or anti-Gal4AD antibodies (Santa Cruz Biotechnol-
ogy, CA, USA) were diluted 1:500 in 10 ml PBST (PBS, 0.05% Tween
(v/v), 1% non-fat milk) and the PBST solution was incubated with the
membranes at 4 C overnight. The secondary antibody, anti-mouseIgG conjugated with HRP, was used at a 1:5000 dilution. The Western
Lightning Chemiluminescence Reagent (Perkin–Elmer Life Science,
Boston, MA, USA) was used as the substrate for detection and the
membrane was exposed to X-ray ﬁlm for visualization.3. Results and discussion
Since biochemical and immunological methods were unable
to detect physical interactions between TRAF6 and Ubc13–
Uev, we suspected that the binding of these proteins may be
transient or unstable during cell extract preparation. Hence,
we used the yeast two-hybrid analysis to determine if they
indeed interact.
Based on our previous Ubc13–Mms2 structural analysis
[17], we predict that TRAF6 may interact with Ubc13, since
Ubc13 is a true E2 and, after binding to Mms2, a surface
predicted to interact with a RING ﬁnger protein is still
available. Fig. 1A shows that mTRAF6 indeed interacts with
Ubc13 based on a reconstituted transactivation of the PGAL1-
lacZ reporter in strain Y190. This interaction is dependent on
the co-existence of Ubc13 and mTRAF6, as neither construct
showed positive results when combining with the vector. The
interaction is also independent of the fusion partners, as
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produce positive results. However, a stronger interaction ap-
pears to occur when Ubc13 is fused with Gal4BD and
mTRAF6 is fused to Gal4AD. Quantitative b-gal analysis
further conﬁrmed such an interaction. The PGAL2-ADE2 re-
porter gene in strain PJ69-4a was reported to be highly strin-
gent [14]. We found that the mTRAF6–Ubc13 interaction
is able to confer growth on SD-Ade as well as SD-His+5 mM
3-AT plates (Fig. 1B). Similar experiments also showed inter-
action between hTRAF6 and Ubc13 (data not shown). Nev-
ertheless, one has to bear in mind that the strength of
interaction between TRAF6 and Ubc13 is signiﬁcantly less
than that between hMms2 and Ubc13, as judged by a semi-
quantitative X-gal ﬁlter assay (see Fig. 3C), as well as in vitro
protein–protein interaction assays showing that while hMms2
and Ubc13 are able to form a stable complex under various
conditions [18], we were unable to detect such a physical in-
teraction using puriﬁed hUbc13 and mTRAF6 (data not
shown).
The positive identiﬁcation of a TRAF6–Ubc13 interaction
does not rule out the possibility that another partner of the
Ubc13–Uev complex is involved in direct contact with
TRAF6, since Uev is a structural homolog [11] of Ubc13, can
potentially bind the TRAF6 RING ﬁnger, and is absolutelyFig. 2. Predicted mTRAF6 domains and domain deletion/mutagenesis ana
deletion/mutation constructs. A few restriction sites used for deletion analysis
mutation within the RING ﬁnger domain. B: Deletion and mutagenesis anal
were co-transformed and the transformants were analyzed by various assaysrequired for TRAF6- and Ubc13-mediated ubiquitination
[4,5]. It also does not rule out the possibility that the observed
TRAF6–Ubc13 interaction in the yeast two-hybrid assay is
mediated by a Uev in host cells, since Mms2 in yeast cells is
able to form a complex with mammalian Ubc13 to allow it to
functionally complement the yeast ubc13 null mutant [19].
There are two human Uev homologs, hMms2 and Uev1, that
share >90% amino acid sequence identity in their core do-
mains and both are able to functionally complement the yeast
mms2 null mutant [11]. We found that while both Uev1 and
hMms2 are able to form complexes with Ubc13, neither can
directly interact with TRAF6 in the yeast two-hybrid assay
(Fig. 1B). This result further supports the direct interaction
between TRAF6 and Ubc13.
TRAF6 contains several predicted functional domains
(Fig. 2A), including an N-terminal RING ﬁnger, ﬁve zinc-
ﬁnger repeats embedded in a CART domain, a mushroom-like
TRAF domain consisting of coiled-coil TRAF-N (‘‘stalk’’)
and TRAF-C (‘‘head’’) [20]. In order to determine which do-
main(s) of TRAF6 is required for its interaction with Ubc13,
we tested diﬀerent mTRAF6 deletion constructs for their
ability to interact with Ubc13 in the yeast two-hybrid assay.
Deletion of the C-terminal half of TRAF6 containing TRAF
domains does not aﬀect interaction with Ubc13, whereaslysis. A: A schematic diagram of mTRAF6 functional domains and
are marked with arrows. The arrowhead points to the position of C70S
ysis of mTRAF6 in a yeast two-hybrid assay. Both Y190 and PJ69-4a
as described in Fig. 1 legend.
Fig. 3. Identiﬁcation of amino acid residues important for Ubc13 to
interact with a RING-ﬁnger motif. A: Predicted Ubc13 surface that
interacts with a RING-ﬁnger motif. The Ubc13 structure ([17], blue) is
oriented after UbcH7 based on the structure of UbcH7-c-Cbl [23].
Only the RING-ﬁnger motif of c-Cbl (green) is shown, with zinc atoms
shown in maroon. Ubc13 residues shown in space-ﬁll are those that fall
in proximity to the interface between Ubc13 and the RING ﬁnger. Red
residues are those conserved between UbcH7 and Ubc13, whereas the
M64 residue (in yellow) is unique to Ubc13. The corresponding F63 in
UbcH7 was thought to be important to provide speciﬁcity for the E3
[23]. B: Amino acid sequence alignment of Ubc13 from human (Hs),
Drosophila (Dm), Schizosaccharomyces pombe (Sp) and Saccharomyces
cerevisiae (Sc) with UbcH7. Residues indicated by red and yellow
boxes correspond to those shown in A. Note that the Met residue in
yellow is identical among all Ubc13 but diﬀers from UbcH7. C: The
Ubc13 M64A substitution abolishes its interaction with mTRAF6.
Y190 cells, co-transformed with Gal4AD and Gal4BD construct, were
replicated on SD-Trp-Leu plates and independent colonies were tested
by a ﬁlter assay. Two representative colonies from each treatment are
shown after 36-h incubation at 30 C. Relative b-gal activity is mea-
sured by the time required to develop blue color and scored as follows:
++++, within 0.5 h; +++, 0.5–1.5 h; ++, 1.5–3 h; +, 3–5 h. Colonies
remaining colorless after 12 h were considered negative.
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domains completely abolishes Ubc13 interaction (Fig. 2B).
Further deletion of the CART/zinc ﬁngers or the RING ﬁnger
also abolished the interaction of TRAF6 with Ubc13 (data not
shown), indicating that the N-terminal RING and zinc ﬁngers
are required for the interaction. However, one cannot rule out
the possibility that deletion of CART or the RING ﬁnger
motif aﬀects its proper folding or destabilizes the protein. To
address this question, we speciﬁcally asked if the RING ﬁnger
motif of TRAF6 is absolutely required for the interaction with
Ubc13, since many RING ﬁnger proteins are found to func-
tion as an E3 [21,22] and their RING ﬁngers appear to be
required for the speciﬁc E2–E3 interaction [23]. If TRAF6
indeed functions as an E3 for Lys-63 mediated polyubiquiti-
nation, one would predict that its RING ﬁnger motif is es-
sential for binding to Ubc13. It is known that the N-terminal
Cys residue within the RING ﬁnger is essential for metal
binding and function [24]. When the corresponding C70 is
mutated to a conserved residue Ser, mTRAF6 was no longer
able to interact with Ubc13 (Fig. 2B). The lack of interaction is
not due to reduced expression of the mutant TRAF6 gene or
the unstable mutant protein in the yeast cells, as judged by
Western-blot analysis (data not shown).
In order to further conﬁrm the direct interaction between
TRAF6 and Ubc13, we sought to identify the Ubc13 surface
region essential for TRAF6 binding. The crystal structure of
an E2 (UbcH7)-E3 (c-Cbl) complex has been reported [23] and
c-Cbl contains a RING ﬁnger motif essential for the complex
formation. By superimposing and subsequently replacing
Ubc13 [17] for UbcH7 in the UbcH7-Cbl crystal structure
(Fig. 3A), we identiﬁed residues of the E2–E3 interface that are
conserved between Ubc13 and UbcH7 (Figs. 3A and B, red).
The sequence alignment of UbcH7 with Ubc13 from various
sources (Fig. 3B) indicates that within this interaction region,
the hUbc13 M64 residue is not conserved with UbcH7; how-
ever, it is invariable among all Ubc13 homologs (Figs. 3A and
B, yellow). The M64A single amino-acid substitution in Ubc13
completely abolishes its interaction with TRAF6 but does not
have apparent eﬀects on its interaction with hMms2 (Fig. 3C).
It was noticed that the corresponding M64A substitution in
yeast Ubc13 also abolished interaction with Rad5 [25], a
RING-ﬁnger protein involved in error-free DNA postreplica-
tion repair [26] through polyubiquitination of PCNA [27].
Taken together, the deletion and site-speciﬁc mutagenesis re-
sults strongly support our structural model proposed in
Fig. 3A.
To ask if the observed physical interaction between TRAF6
and hUbc13 has biological relevance, the small interference
RNA (siRNA) technology was applied to suppress endoge-
nous hUBC13 expression and it was found that siRNA against
hUBC13 reduced TRAF6-mediated NF-jB activation in cul-
tured human embryonic kidney 293T cells [28].
It has been shown that the family of TRAF proteins un-
dergoes self-association [29]. However, evidence for the
TRAF6 self-interaction has not been reported. The yeast two-
hybrid analysis is ideal to study protein self-interactions. As
shown in Fig. 4, full-length TRAF6 is able to interact with
itself and the N-terminus appears to be suﬃcient for this in-
teraction. Deletion of the RING ﬁnger domain or the C70S
substitution within the RING ﬁnger motif abolishes the in-
teraction, suggesting that the RING ﬁnger motif is required
for homo-oligomerization.In summary, we have demonstrated a direct interaction be-
tween TRAF6 and Ubc13 using the yeast two-hybrid assay.
Since such an interaction cannot be readily detected by other
in vitro methods, we propose that the association is probably
transient, which is in contrast to the stable Ubc13–Uev com-
plex [18]. We also demonstrated that two mammalian Uevs,
Fig. 4. The N-terminal region and RING ﬁnger are required for
mTRAF6 self-interaction. Y190 cells co-transformed with a full-length
TRAF6 and various TRAF6 deletion constructs were tested by a ﬁlter
assay and a quantitative b-gal assay as expressed in MU.
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are dispensable for the TRAF6–Ubc13 interaction. However,
the E2 complex consisting of Ubc13 and a Uev is required for
Lys-63 polyubiquitination and it is most likely that TRAF6
will interact with the E2 complex rather than Ubc13 alone in
vivo. TRAF6 may serve as an E3 or as a target for Ubc13-
mediated Lys-63 chain assembly. While the latter has been
demonstrated experimentally, evidence to support its E3 role
has not been reported. We demonstrated that the amino ter-
minus of TRAF6 containing the RING ﬁnger and zinc ﬁnger
domains is essential and suﬃcient for this interaction. The
essential role of the TRAF6 RING ﬁnger motif is further
conﬁrmed by the lack of Ubc13 interaction after a single
conserved amino acid substitution within TRAF6, which is
consistent with the notion that most RING ﬁnger proteins are
indeed E3s.
We were also able to demonstrate that, like other TRAF
proteins, TRAF6 is able to interact with itself. Interestingly,
the amino terminus containing the RING ﬁnger and zinc ﬁnger
domains was also essential and suﬃcient for this self-associa-
tion. It is unclear whether the self-association of TRAF6 is a
prerequisite for its interaction with Ubc13 and if so, what is
the cellular role(s) of this homodimer (or homo-oligomer)
formation.
Due to the lack of a stable interaction between TRAF6 and
Ubc13–Uev, conventional studies to investigate the structure–
function relationship of this important E2–E3 complex are not
feasible. The yeast two-hybrid analysis as demonstrated in this
report provides an alternative method to conduct such inves-
tigations. Furthermore, recent studies suggest that in addition
to TRAF6, other RING-ﬁnger proteins, including TRAF2
[30,31] and Chfr [32], as well as non-RING-ﬁnger proteins,
such as Bcl10 and paracaspase [28], also function in Ubc13-
mediated Lys-63 polyubiquitination. Hence, the yeast two-
hybrid assay will be a useful tool in determining physical
interactions between the above proteins and Ubc13–Uev, as
well as in screening for additional Ubc13–Uev interacting
proteins.Acknowledgements: We thank Drs. R.B. Brazas, Z.J. Chen, V.M.
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